Mr. Valian is a leader in global biopharmaceutical development in eye care. He has extensive experience across corneal disease, surgical and interventional glaucoma, retina, and consumer eye care, with a consistent record of building high-performing teams, executing strategic product launches, and advancing patient-centric innovation. Prior to joining Emmecell, Ramin held senior leadership roles at Allergan and AbbVie, where he played key roles in global strategy, clinical development, and commercialization of multiple high-impact ophthalmic products. 

Dr. Kunzevitzky has more than 20 years of experience in ophthalmology with a focus on innovation and regenerative medicine. She has played a key role in building and scaling the company’s operations and infrastructure. Noelia leads execution across pre-clinical development, cell manufacturing, regulatory strategy, and clinical development. She plays a central role in advancing Emmecell’s magnetic cell delivery platform toward pivotal clinical development and commercialization. 

Dr. Roger Goldberg is a vitreoretinal surgeon with expertise in clinical trial design and implementation. He did his clinical training in ophthalmology at the Bascom Palmer Eye Institute and vitreoretinal fellowship at Tufts University. Previously, Roger worked for McKinsey & Co. in healthcare consulting. He received his BA, MD, and MBA from Yale.

Mr. Allouche brings over 25 years of experience in finance leadership in both public and pre-IPO companies, including biopharmaceutical, medical devices, and diagnostics. He most recently served as CFO at Avellino Lab, LensGen, Dermavant Sciences and held finance leadership roles at Revance Therapeutics and CareDx. He also spent over a decade at PricewaterhouseCoopers in Audit and Transaction services. Cyril is a California Certified Public Accountant and holds a Master of Accountancy from University of Georgia and a Master of Business Administration from University of Paris-East.

Dr. Jeffrey Goldberg is Professor and Chair of Ophthalmology and Director of the Byers Eye Institute at Stanford University. His focus is on regenerative medicine in eye and vision research,  and on developing novel molecular, stem cell, and nanotherapeutics approaches for eye repair. Jeff completed his clinical training in ophthalmology and glaucoma at the Bascom Palmer Eye Institute. He received his BS magna cum laude from Yale, and his MD and PhD from Stanford.

Mr. Mazzo is Executive Chair of Neurotech, a private clinical-stage biotechnology company developing therapies for chronic eye diseases. A highly respected ophthalmic industry leader with more than 40 years of experience in medical devices, Mr. Mazzo is internationally recognized for building and leading world-class organizations. His leadership roles include CEO of Allergan’s North American and European eye care businesses; chairman, president, and CEO of Advanced Medical Optics; EVP of Abbott’s global ophthalmology business; executive chair and CEO of AcuFocus; and global president of ophthalmic devices at Carl Zeiss Meditec.

Mr. Donaghy has over thirty years experience in private equity investing. He serves as the President and is on the Board of Holding Capital Groups' principal investment entities. He also serves (or has served) on the Boards of portfolio companies in precision injection molding, building materials, men's apparel, wire and cable, concrete products, and metal and rubber manufacturing industries amongst others. Mr. Donaghy holds a BS in Business Administration from the University of Nebraska and an MBA from Pace University.